Soquelitinib

Phase 3

00%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

Nov '26

CRVSPhase 3$1.0B

Soquelitinib Phase 3 Est. Readout

Soquelitinib• Peripheral T-Cell Lymphoma, Not Otherwise Specified150

Nov 2026~ConfirmedSTALE

00%

Competitive Landscape

0 competitors in Peripheral T-Cell Lymphoma, Not Otherwise Specified

Drug Information

Target Indication

Peripheral T-Cell Lymphoma, Not Otherwise Specified

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

CRVS

Corvus Pharmaceuticals, Inc.

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts